Drugs that contain Fosdenopterin Hydrobromide
1. Nulibry patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7504095 | SENTYNL THERAPS INC | Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency |
Jan, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-342) | Feb 26, 2028 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| M(M-286) | Oct 27, 2025 |
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: Method of treating molybdenum cofactor deficiency type a
Dosage: POWDER;INTRAVENOUS
More Information on Dosage
NULIBRY family patents
